Video

Jabil Capabilities Update November 2026: Bioavailability/ Solubility

Poor aqueous solubility threatens clinical exposure for many oral drug candidates, whether dealing with high-melting-point "brick dust" compounds or lipophilic "greaseball" molecules. Overcoming these hurdles without wasting scarce active pharmaceutical ingredients (API) starts with in silico modeling to rapidly narrow excipient options before selecting a targeted delivery platform—such as wet media milled nanosuspensions, lipid-based systems, solvent-coated solid dispersions, or cyclodextrin complexes.

At PII, a Jabil company, continuous scientific oversight and integrated analytical testing connect early formulation selection directly to commercial manufacturing on a single campus. From stabilizing submicron particle sizes to handling potent compounds and DEA-controlled substances, aligning physicochemical characterization with scalable equipment trains keeps clinical timelines intact.

Watch the full presentation to see how data-driven formulation strategies and real-world nanosuspension development deliver up to 13-fold higher human exposure for challenging oral molecules.

Access The Video!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Outsourced Pharma